Cato Research Ltd.
http://www.cato.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cato Research Ltd.
SanoGene Therapeutics Inc.
SanoGene Therapeutics thinks it will be able to enhance outcomes for glioblastoma patients by following the unavoidable brain surgery with an injection of targeted plasmids containing short sequences of RNA.
Biotechnology North of the Border
A venture-backed Canadian biotechnology industry is in its infancy, but faced with hostile capital markets, start-ups need clear exit plans. Consolidation's already started.
Human Genome's Risk-Management Math
Human Genome Sciences believes its lead in genomics--it claims to have nearly all human genes in its database--is already letting it beat the biotech odds in the clinic by allowing it to pick better proteins to develop and then follow them up with a virtually inexhaustible source of new candidates. Skeptics don't like the company's arithmetic.
Gene Therapy: Location, Location, Location
The new gene therapy start-ups are learning to live with the technology’s limitations--and even to exploit them. While systemic treatments have generally failed, largely because doctors couldn’t deliver high-enough and frequent-enough doses to overcome the relatively low transfection rates and short-term expression, new companies are targeting localized diseases, in vascular medicine, wound care and certain neurological conditions, in which treatment doesn’t require long-term expression and where direct delivery of genes maximizes the effective dose.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice